Differential interactions of camptothecin lactone and carboxylate forms with human blood components.

The intrinsic fluorescent emissions from the lactone and carboxylate forms of camptothecin have been exploited in order to elucidate their markedly different interactions with the various components of human blood. In phosphate-buffered saline (PBS) at pH 7.4, human serum albumin (HSA) preferentially binds the carboxylate form with a 150-fold higher affinity than the lactone form; these interactions result in camptothecin opening more rapidly and completely in the presence of HSA than in the protein's absence [Burke, T.G., & Mi, Z. (1993) Anal. Biochem. 212, 285-287]. In human plasma, at pH 7.4 and 37 degrees C, we have observed camptothecin lactone to open rapidly and fully to the carboxylate form (t1/2 = 11 min; % lactone at equilibrium, 0.2%). Substitution of a 10-hydroxy moiety into the camptothecin fluorophore makes the agent's emission spectrum highly sensitive to microenvironment polarity; we have observed pronounced blue shifting (from 530 to 430 nm) in the emission spectra of the hydroxy-substituted carboxylate both upon HSA association as well as upon drug dissolution in organic solvents of low dielectric strength. Hence, it appears that camptothecin carboxylate's fluorophore locates in a hydrophobic binding pocket in native HSA. Ionic interactions also appear to strongly affect binding between camptothecin carboxylate and the HSA binding pocket, since a 6-fold increase in solution salt concentration diminished camptothecin carboxylate binding by 10-fold. Our findings that HSA denaturation abolishes high-affinity binding indicate that interactions of the carboxylate drug form are specific for the native HSA conformation. Interestingly, high-affinity binding of the carboxylate appeared not to occur in the presence of other blood proteins, such as gamma-globulin, alpha 1-acid glycoprotein, fibrinogen, and the oxy and deoxy forms of hemoglobin. In whole blood versus plasma, camptothecin was found to display enhanced stability (t1/2 value of 22 min and a lactone concentration at equilibrium value of 5.3%). The enhanced stability of camptothecin in human blood was found to be due to drug associations with the lipid bilayers of red blood cells. Camptothecin lactone partitions into the lipid bilayers of erythrocytes, with the drug locating in a hydrophobic environment protected from hydrolysis.

[1]  D C Carter,et al.  Structure of serum albumin. , 1994, Advances in protein chemistry.

[2]  L. Sann,et al.  Evolution of serum prealbumin, C-reactive protein, and orosomucoid in neonates with bacterial infection. , 1984, The Journal of pediatrics.

[3]  E K Rowinsky,et al.  The current status of camptothecin analogues as antitumor agents. , 1993, Journal of the National Cancer Institute.

[4]  J. Beijnen,et al.  Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution. , 1990, Journal of pharmaceutical and biomedical analysis.

[5]  T. Burke,et al.  The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. , 1994, Journal of medicinal chemistry.

[6]  A. McPhail,et al.  Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2 , 1966 .

[7]  T. Burke,et al.  Preferential binding of the carboxylate form of camptothecin by human serum albumin. , 1993, Analytical biochemistry.

[8]  M. Ishiguro,et al.  Structure of 1 -acid glycoprotein. The complete amino acid sequence, multiple amino acid substitutions, and homology with the immunoglobulins. , 1973, Biochemistry.

[9]  T. Burke,et al.  Location and dynamics of anthracyclines bound to unilamellar phosphatidylcholine vesicles. , 1985, Biochemistry.

[10]  T. Furuta,et al.  Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. , 1990, Cancer research.

[11]  X. Gao,et al.  Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine. , 1994, Journal of pharmaceutical sciences.

[12]  M. Wani,et al.  Plant antitumor agents. 28. Resolution of a key tricyclic synthon, 5'(RS)-1,5-dioxo-5'-ethyl-5'-hydroxy-2'H,5'H,6'H-6'-oxopyrano[3' ,4'- f]delta 6,8-tetrahydro-indolizine: total synthesis and antitumor activity of 20(S)- and 20(R)-camptothecin. , 1987, Journal of medicinal chemistry.

[13]  L. Liu,et al.  Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. , 1988, Cancer research.

[14]  R. Cundall,et al.  Fluorescence lifetime and quenching studies on some interesting diphenylhexatriene membrane probes , 1983 .

[15]  T. Burke,et al.  Liposomal stabilization of camptothecin's lactone ring , 1992 .

[16]  G. Manikumar,et al.  Plant antitumor agents. 25. Total synthesis and antileukemic activity of ring A substituted camptothecin analogues. Structure-activity correlations. , 1987, Journal of medicinal chemistry.

[17]  R. D. Spencer,et al.  MEASUREMENTS OF SUBNANOSECOND FLUORESCENCE LIFETIMES WITH A CROSS‐CORRELATION PHASE FLUOROMETER * , 1969 .

[18]  J. Supko,et al.  Liquid Chromatographic Analysis of 9-Aminocamptothecin in Plasma Monitored by Fluorescence Induced upon Postcolumn Acidification , 1992 .

[19]  L. Liu,et al.  DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. , 1989, Science.

[20]  D. Carter,et al.  Atomic structure and chemistry of human serum albumin , 1992, Nature.

[21]  G. L. Jendrasiak Halide interacti witonh phospholipids: Proton magnetic resonance studies , 1972 .

[22]  L. Liu,et al.  Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. , 1989, Cancer research.

[23]  T. Burke,et al.  Structural basis of anthracycline selectivity for unilamellar phosphatidylcholine vesicles: an equilibrium binding study. , 1985, Biochemistry.

[24]  F. Bright,et al.  Detailed Investigation of 2-(p-Toluidinyl)naphthalene-6-Sulfonate (TNS) Binding to Bovine Serum Albumin (BSA) by Steady-State and Time-Resolved Fluorescence Spectroscopy , 1993 .

[25]  T. Burke,et al.  Lipid bilayer partitioning and stability of camptothecin drugs. , 1993, Biochemistry.

[26]  T. Burke,et al.  Ethyl substitution at the 7 position extends the half-life of 10-hydroxycamptothecin in the presence of human serum albumin. , 1993, Journal of medicinal chemistry.

[27]  J. Dodge,et al.  The preparation and chemical characteristics of hemoglobin-free ghosts of human erythrocytes. , 1963, Archives of biochemistry and biophysics.

[28]  J. Supko,et al.  A Reversed-Phase HPLC Method For Determining Camptothecin In Plasma With Specificity For the Intact Lactone Form of the Drug , 1991 .

[29]  R. Hertzberg,et al.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.

[30]  J. Helbert,et al.  EVALUATION OF A STROMA-FREE HEMOGLOBIN SOLUTION FOR USE AS A PLASMA EXPANDER , 1967, The Journal of experimental medicine.

[31]  M. Eftink,et al.  Fluorescence quenching of indole and model micelle systems , 1976 .

[32]  M. Potměšil,et al.  Camptothecins: from bench research to hospital wards. , 1994, Cancer research.

[33]  Russell J. Eilers,et al.  Notification of final adoption of an international method and standard solution for hemoglobinometry specifications for preparation of standard solution. , 1967, Blood.